Citius Oncology, Inc.
CTOR
$2.09
$0.2010.58%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 33.00% | 52.54% | 64.52% | 98.55% | 129.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.48% | 48.88% | 49.27% | 69.72% | 30.74% |
| Operating Income | -34.48% | -48.88% | -49.27% | -69.72% | -30.74% |
| Income Before Tax | -35.33% | -48.88% | -49.27% | -69.72% | -30.74% |
| Income Tax Expenses | 62.60% | 41.74% | 20.87% | 0.00% | -63.64% |
| Earnings from Continuing Operations | -36.13% | -48.65% | -48.22% | -66.56% | -21.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.13% | -48.65% | -48.22% | -66.56% | -21.44% |
| EBIT | -34.48% | -48.88% | -49.27% | -69.72% | -30.74% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -29.29% | -42.76% | -44.39% | -64.81% | -21.46% |
| Normalized Basic EPS | -28.62% | -43.16% | -45.53% | -68.00% | -30.70% |
| EPS Diluted | -29.29% | -42.76% | -44.39% | -64.81% | -21.46% |
| Normalized Diluted EPS | -28.62% | -43.16% | -45.53% | -68.00% | -30.70% |
| Average Basic Shares Outstanding | 5.32% | 3.82% | 2.32% | 0.82% | 0.00% |
| Average Diluted Shares Outstanding | 5.32% | 3.82% | 2.32% | 0.82% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |